Most carcinomas have characteristic chromosomal aneuploidies specific to the tissue of tumor origin. The reason for this specificity is unknown. As aneuploidies directly affect gene expression, we hypothesized that cancer-type specific aneuploidies, which emerge at early stages of tumor evolution, confer adaptive advantages to the physiological requirements of the tissue of origin. To test this hypothesis, we compared chromosomal aneuploidies reported in the TCGA database to chromosome arm-wide gene expression levels of normal tissues from the GTEx database. We find that cancer-type specific chromosomal aneuploidies mirror differential gene expression levels specific to the respective normal tissues which cannot be explained by copy number alterations of resident cancer driver genes. We show that cancer-type specific aneuploidies "hard-wire" chromosome arm-wide gene expression levels present in normal tissues and propose that the clonal evolution of cancer is initiated by tissue-specific transcriptional requirements.
The generally accepted concept of tumorigenesis is based on the notion that genetic alterations that result in malignant transformation are a priori tumor promoting. These alterations occur as activating mutations or amplifications of proto-oncogenes, inactivating mutations or deletions of tumor suppressor genes, and chromosomal translocations, that result in the constitutive activation of proliferation-promoting or the inhibition of anti-cell death pathways 1 . The initial driver of tumorigenesis would therefore be "oncogenic" and inherent to the emerging cancer cell.
In solid tumors of epithelial origin, i.e., carcinomas, and in certain other solid tumors such as glioblastoma multiforme and malignant melanoma, aneuploidies of specific chromosomes define the landscape of somatically acquired genetic changes [2] [3] [4] [5] [6] . Remarkably, the distribution of ensuing genomic imbalances is strictly cancer-type specific 6, 7 . For instance, colorectal carcinomas are defined by extra copies of chromosomes and chromosome arms 7, 8q, 13q and 20q, accompanied by losses of 8p, 17p and 18q 8 . In contrast, cervical carcinomas invariably carry gains of chromosome arms 1q and 3q. In other words, a gain of 3q is not observed in colorectal cancer, and cervical carcinomas do not have copy number gains of, e.g., chromosomes 7 or 13q (Fig. 1A) . Tissue-specific chromosomal aneuploidies emerge in dysplastic, i.e.
, not yet malignant, lesions (Fig. 1B) , that, when these aneuploidies are present, are prone to progress to invasive disease 9, 10 .
The cancer-type specific distribution of genomic imbalances was recently confirmed in two comprehensive pan-cancer analyses of several thousand tumors 11, 12 . The pattern of chromosome-arm and whole chromosome gains and losses allows classification of tumor entities. Of note, this distinctive power dissipates when solely considering focal copy number alterations (defined as copy number alterations with lengths < 0.5 chromosome arms) including, but not limited to, presumed or known oncogenes or tumor suppressor genes 5, 11 .
The reason for the remarkable cancer-type and tissue specificity of chromosomal aneuploidies is not known. What is well known, however, is that chromosome-wide alterations of gene expression levels follow genomic copy number changes 13, 14 , i.e., the transcripts of genes that are located on gained chromosomes are more, and those on lost chromosomes are less abundant. This correlation has been firmly established in primary human carcinomas, in derived cell lines, and in experimental models 13, [15] [16] [17] [18] . Given the direct effect of genomic copy number on gene expression, chromosomal aneuploidies are therefore a mechanism by which gene dosage can be altered in a "hard-wired" fashion to persist in subsequent generations. This correlation is exemplarily shown for colorectal and cervical cancer based on TCGA data (Fig. 1C ) 19, 20 .
We therefore hypothesized that cancer-type specific chromosomal aneuploidies create a transcriptional landscape beneficial for cells in the respective normal tissue of origin. Our hypothesis predicts that cancer-specific chromosomal imbalances mirror gene expression patterns in the normal tissues of origin. For example, we surmise that the gain of chromosomes 7
and 13q in colorectal cancers means that genes located on these chromosomes are expressed in normal colorectal tissue more abundantly than in other normal tissues. Accordingly, tissuespecific aneuploidies at early stages of tumorigenesis may not reflect an a priori oncogenic stimulus, but rather manifest a proliferative advantage triggered by the physiological requirements of the respective normal tissue.
Assuming random chromosome segregation errors in different tissues, cells that gain chromosomes required for physiological function would be selected for in the context of the respective tissues, triggering a "benign" clonal expansion. The increasing pool of such cells, associated with higher tissue-specific fitness, higher proliferative activity or less cell-death, however, may increase the risk for subsequent genetic damage 21 , while maintaining the overexpression of genes that are required for the physiology of the organ.
To verify or falsify our hypothesis, we analyzed whether cancer-type specific patterns of chromosomal aneuploidies correlate with patterns of chromosome arm-wide gene expression in the respective normal tissues. If the hypothesis is valid, one would expect, for instance, that genes on chromosome arm 13q, which is frequently gained in colorectal, but not in other cancers, are expressed higher in normal colorectal epithelium compared to other normal tissues.
RESULTS

Comparison of cancer-type specific chromosome arm-wide genomic imbalances with the chromosome arm-wide gene expression levels in their respective normal tissues
Copy number alterations based on the TCGA database were extracted from Taylor and colleagues 12 for 15 different tumor entities and are consistent with previous results 2, 3, 6, 11 . Gene expression levels in the respective normal tissues were retrieved from the GTEx database 22 . We found that, consistent with our hypothesis, across distinct cancer entities, gene expression levels in normal tissues are upregulated on those chromosomes that were gained in the respective tumors, whereas expression levels were lower on lost chromosomes ( Fig. 2A) . The correlations of arm-level copy number changes in the tumors and the arm-wide gene expression levels in the corresponding normal tissues were invariably positive (Fig. 2B,C) . With the exception of acute myeloid leukemia, a tumor without recurrent copy number changes (see Fig. 2A ), the correlations were statistically highly significant, and could not be obtained with randomly shuffled data (empirical P-value <0.001). 3B) . We also showed that frequently gained chromosomes across cancer types correlate with chromosome arm-wide gene expression level in the respective normal tissues better than chromosomes that are rarely gained (Fig. 3C) . Finally, we compared chromosome arm-wide gains in cervical and colorectal cancer with chromosome arm-wide gene expression levels in the respective normal tissues. The results confirm our findings: more genes on chromosome arms 1q and 3q, which are gained at early stages of cervical tumorigenesis, are expressed in normal cervix compared to normal colon (Fig. 3D ).
Classification
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Cancer-type specific aneuploidies cannot be explained by the chromosome arm-wide distribution of cancer genes and methylation patterns
One possible explanation for the correlation of cancer-type specific chromosomal aneuploidies with chromosome arm-wide gene expression levels in the respective normal tissues could be the distribution of oncogenes and tumor suppressor genes 5 . We therefore asked whether the chromosome-arm wide distribution of oncogenes and tumor suppressor genes known to be involved in different tumor types correlates with the acquisition of cancer-type specific imbalances. For the 15 tumor types analyzed we found that the gain or loss of oncogenes or tumor suppressor genes, respectively, does not match the patterns of chromosome arm-wide copy number changes observed in the corresponding tumors ( Supplementary Fig. 2 ). This implies that the distribution of cancer-type genomic imbalances is likely not a reflection of specific cancer genes acting in the respective tumors, which is in accordance with previous results obtained by
Beroukhim and colleagues 11 . Potential mechanisms regulating tissue-specific chromosome armwide gene expression include DNA methylation, histone acetylation and higher order nuclear organization, the 4D Nucleome 23 . Data for chromosome-specific histone acetylation and nuclear organization are not readily available, but the Gene Expression Omnibus (GEO) database provides genome-wide methylation patterns. Based on these data we analyzed chromosome armwide methylation patterns for 11 tissues from 765 samples (Materials and Methods). While differences in the methylation status of specific genes and their expression were readily apparent, arm-level differences in methylation levels did not allow the discernment of specific tissues from each other (Supplementary Fig. 3 ) and could not explain the chromosome-arm wide tissuespecific gene expression patterns.
DISCUSSION
Overall, our results indicate that differences of chromosome arm-wide gene expression levels in normal human tissues are enhanced by the acquisition of aneuploidies in the cognate tumors, suggesting a non-oncogenic, tissue-specific physiological basis for clonal expansion.
Interestingly, Sack and colleagues 24 have demonstrated that the inclusion of tissue-specific growth promoting genes strengthens the correlation between chromosome arm loss/gain ratios and the proliferation-driving capability of each chromosome-arm in breast and pancreatic cancers. A general, yet not tissue-specific, role of copy number alterations and metabolic selection pressure was reported by Graham and colleagues 25 . Of note, several publications point to a reduction of cellular fitness as a consequence of general aneuploidy [26] [27] [28] . We show that, unlike general aneuploidy, tissue-specific aneuploidies that enhance chromosome arm-wide normal tissue-specific gene expression levels result in clonal expansion. Notably, we previously showed that the gain of chromosome 13 in colorectal cancer activates both Notch and Wnt signaling 29 , and that the acquisition of extra copies of chromosome 7 results in upregulation of the Wnt pathway (Braun et al., accepted for publication, Neoplasia), which supports our finding that the enhancement of tissue-type specific chromosome arm-wide gene expression levels by copy number alterations can promote cellular fitness.
In conclusion, we found that (i) chromosome arm-wide gene expression patterns are tissue-type specific and predict the respective normal tissue of origin.
(ii) The acquisition of cancer-type specific aneuploidies mirrors chromosome arm-wide gene expression patterns of the respective normal tissues, i.e., the changes are inherited after cell division and become "hardwired". Our observations are schematically summarized in Fig. 4 . Rather than being acquired and maintained based on an a priori oncogenic advantage, the dominant and ubiquitous cancertype specific chromosomal aneuploidies are under strong selection to optimally fit the physiological transcriptional requirements of their respective normal tissues.
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MATERIALS AND METHODS
Tissue and tumor type inclusion
In this study, the cancer types and respective normal tissues included were all those for which there was availability of (1) genomic copy number of the cancerous tissue from The Cancer Genome Atlas (TCGA) and (2) gene expression of normal tissues from Genotype-tissue Expression (GTEx) Database. Epithelial tumor types with no chromosomal aneuploidy (i.e. no chromosomal arm was gained or lost in 25% of the samples, as defined throughout this study, see below) were excluded from the analysis. For tissues with more than one matching cancer type in TCGA (e.g., lung), the cancer type with the larger number of samples with somatic copy number alteration data was selected (e.g., TCGA LUAD rather then LUSC).
Computation of chromosomal arm gain and loss score in cancerous tissues
We used the TCGA sample-wise chromosomal arm gain and loss data provided 12 , where the ploidy was determined via the ABSOLUTE algorithm 30 . Each segment was designated as amplified, deleted, or neutral compared to the ploidyof each sample. Tumors altered <20% were considered "non-aneuploid," and others were designated "other. 
Computation of chromosome-arm level gene expression changes in normal tissues
We count the number of up and down regulated genes in each arm, for every cancer type, using 
Correlation of arm level regulation across normal tissues
We evaluate the correlation between the arm gain/loss score in each cancer type and the score of up/down-regulation in each normal tissues via two approaches (for both using Spearman rank correlation rho and P-value):
1. Arm-level correlation: for each chromosomal arm, we correlate the number of samples with gain of that arm for each cancer type, with the number of up regulated genes in that arm for the corresponding normal tissues. Similarly, for each arm we correlate the number of samples with loss of that arm for each cancer type, with the number of down regulated genes in that arm of the corresponding normal tissues.
2. Tumor/normal tissue correlation: For each tumor type considered, we correlate the arm aneuploidy score with the arm gene expression regulation score of the respective normal tissue.
Normal tissue classification
To classify normal tissues using the chromosomal-arm regulation map of those tissues, we calculate for each sample, the median gene expression level of the genes in each chromosomal arm. We then perform K-Nearest-Neigbors (KNN, with K=5) classification with a Leave-OneOut cross validation (LONCOV), aiming to classify each sample by the median chromosomal arm expression of the normal tissues that are closest to it, and calculate the resulting accuracy (percentage of correctly classified samples in the LONCOV). For comparison, we perform a similar KNN analysis with the full gene expression data.
Evaluating the correlation between arm-level gain and loss in tumors with the localization of oncogenes and tumor suppressor genes
We downloaded oncogene and tumor suppressor classifications for each gene in each tissue from 31 . Then, for each arm and tissue, we counted the number of genes on that arm classified as oncogene (respectively tumor suppressor) resulting in a tissue specific oncogene (respectively, tumor suppressor) enrichment profile for the arm. Finally, to evaluate whether an arm is gained more often in tissues where it harbors oncogenes (respectively, lost more often in tissues where it harbors tumor suppressors) we measure the spearman rank correlation between the tissue-specific gain (respectively, loss) frequency of that arm and its tissue specific oncogene (respectively, tumor suppressor) enrichment profile.
Tissue specific methylation analysis
We curated a list of 18 Illumina 450K methylation datasets from Gene Expression Omnibus covering tissues from 11 organs. These datasets span different studies comparing methylation profiles of tissues between diseased and normal control individuals. We only selected methylation profiles of normal control individuals for further analysis. Multiple datasets containing samples coming from the same tissue were merged to generate one methylation dataset. (See Supplementary Table 1 for more information on each of the datasets). In order to do a comparison of methylation levels on each arm across tissues, we first pre-process each dataset in the following three steps.
1. Filtering out probes overlapping with single nucleotide polymorphisms to control for population specific differences in methylation levels 32 .
2. Rescaling the beta values between type 1 and type 2 probes using beta mixture quantile normalization. This minimizes technical differences that may arise between two different probe designs 33 .
3. Rescaling beta values of each sample in a dataset by the median value of the dataset to adjust for dataset-specific differences in methylation levels..
Given a chromosome arm, we find each tissue where that arm is gained in the corresponding cancer (as defined above). We measure the fold change in methylation levels of each probe on that arm in that tissue, relative to tissues where that arm is not gained. Likewise, we find each tissue where the arm is lost in the corresponding cancer (as defined above). We measure the fold change in methylation levels of each probe on that arm in that tissue, relative to tissues where that arm is not lost. Finally, we find each tissue where the arm is neither gained nor lost in the corresponding cancer. We measure the fold change in methylation levels of each probe on that arm in that tissue, relative to tissues where the arm is either gained or lost.
We define >Y . 2 
Inferring which arm aneuploidies occur early in tumorigenesis
For each of the 15 tissues considered, given the aneuploidy profiles of 39 chromosome arms in corresponding primary tumors of different patients, one can partially order these aneuploidies by time using the following score:
This score estimates the likelihood of occurrence of an event given the occurrence of other events. It has been previously shown that the lower this score, the earlier the event 34 . Given that tumors of different tissues may evolve at different rates, we defined an event as early if the event was among the first 10 events after sorting them in increasing order by the above score. Our downstream analyses are robust at more stringent definitions of an early event (i.e., first 9, first 8, first 7, … , first 2, first event; results not shown). With the exception of LAML (no copy number changes), all correlations are highly significant.
Relevant chromosome arms are indicated with different colors. The correlations of the arm-wide methylation and gene expression in normal tissues are not significant.
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